RE: Next RNS11 Jul 2018 00:08
Ah fair enough..thanks for that, Aim4
.I'm genuinely pleased and relieved that you've taken a stab at a decent response instead of avoiding the issue and striking the man. It;'s a fair assessment of medium to long-term 'potential' and direction.
But it still leaves gaping hole in the main assertion that this Market Cap can get anywhere remotely close to £80Mill by September. ie 20p
Being logical and realistic about that , it would mean some sort of input / change in events that added a whopping £70Mill to MC in just a few weeks. As you stated NF001/002 are going through their stages - but that part of the early potential is factored into the share price - as is the Chinese money.
Since the present MC of the company is circa £13/ 14M, with knowledge of those products factored in, it would take a rather radical up-step in development - which sin't on the cards - to get anywhere near double fgure share price.
D Gooding stated in his latest Podcast that other pipeline developments are coming through at VERY early stage.
Nfx has been going (in various guises for 9 years - with still an MC of only £13M), so early -stage Co_crystal additions will not boost the share price in a sustained way, until NF002 gets further advanced. I think the peaks and troughs will continue within 2.5p to 6p range - unless there's some major change (not yet foreseen in drugs development), a Buyout - V unlikely in early stage Pharma, or a massive investment ...and I mean Millions.
I suppose tie ups like the George St capital will add by cumulative effect somewhat, but adding £70Million is something else -and I think we're several trials and tests away from ven thinking in those terms.
I'm also very interested in these "rumours" started by Aberdeenman and perpetuated by you (Aim4) that somehow the Spreadex shares are being transferred.. First it could be a simple sell-off to market, which is entirely possible, OR they are being transferred to another major investor.
Sounds mysterious and alluringly secretive,, but so what?